HC Wainwright reiterated their buy rating on shares of Exelixis (NASDAQ:EXEL – Free Report) in a research note published on ...

Exelixis (NASDAQ:EXEL) said on Wednesday that the U.S. FDA has approved cabozantinib for patients 12 years of age and older ...

The US Food and Drug Administration (FDA) has approved Exelixis’ Cabometyx (cabozantinib) to treat advanced neuroendocrine ...

Shares of Exelixis, Inc. EXEL have risen 13.3% year to date compared with the industry’s growth of 6.6%. The stock has also ...

Guggenheim analyst Michael Schmidt maintained a Buy rating on Exelixis (EXEL – Research Report) on March 26 and set a price target of $42.00.

Stock analysts at Leerink Partnrs increased their Q1 2025 earnings per share (EPS) estimates for shares of Exelixis in a report issued on Wednesday, March 26th. Leerink Partnrs analyst A. Berens now ...

Exelixis (EXEL) announced that preclinical data will be presented for four pipeline molecules at the American Association for ...

After canceling a planned advisory committee meeting, the FDA has approved Exelixis’ Cabometyx for neuroendocrine tumors. | ...

Exelixis (EXEL) on Wednesday announced that the Food and Drug Administration has approved cabozantinib, or Cabometyx, for the treatment of unresectable, locally advanced or metastatic pancreatic ...

In a report released today, Asthika Goonewardene from Truist Financial maintained a Buy rating on Exelixis (EXEL – Research Report). The ...

Exelixis (NasdaqGS:EXEL) saw an 11% share price increase over the last quarter, a period marked by significant achievements ...

Shares of Exelixis, Inc. EXEL have risen 13.3% year to date compared with the industry’s growth of 6.6%. The stock has also outperformed the sector and the S&P 500 Index in this timeframe.